

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Epoetin alfa

INITIATION – chronic renal failure

Prerequisites (tick boxes where appropriate)

- ☐ Patient in chronic renal failure
and
☐ Haemoglobin is less than or equal to 100g/L
and
- ☐ Patient does not have diabetes mellitus
and
☐ Glomerular filtration rate is less than or equal to 30ml/min

or

☐ Patient has diabetes mellitus
and
☐ Glomerular filtration rate is less than or equal to 45ml/min

or

☐ Patient is on haemodialysis or peritoneal dialysis

INITIATION – myelodysplasia*

Re-assessment required after 2 months

Prerequisites (tick boxes where appropriate)

- ☐ Patient has a confirmed diagnosis of myelodysplasia (MDS)
and
☐ Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent
and
☐ Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS)
and
☐ Other causes of anaemia such as B12 and folate deficiency have been excluded
and
☐ Patient has a serum epoetin level of < 500 IU/L
and
☐ The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week

CONTINUATION – myelodysplasia*

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- ☐ The patient's transfusion requirement continues to be reduced with epoetin treatment
and
☐ Transformation to acute myeloid leukaemia has not occurred
and
☐ The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Epoetin alfa - *continued*

INITIATION – all other indications

Prerequisites (tick box where appropriate)

- ☐ Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ For use in patients where blood transfusion is not a viable treatment alternative

Note: Indications marked with * are unapproved indications

I confirm that the above details are correct:

Signed: Date: